Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. m. x. x x. 46/2008 Xx. m. x. x xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. s. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 11. listopadu 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx dopingu xx xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2014 x xxxxx xxxx xxxxxxxxx v xxxxxxxx i pro Xxxxxx republiku. Xxxx xxxxxx xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx překlad xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

¹⁾ Xxxxxxxxxxx úmluva xxxxx xxxxxxx ve xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx od 1. xxxxx 2014

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, S4.4, X4.5 x X6(x) a Xxxxxxxxxx metod X1, X2 a X3.

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmaceutická xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně schválena xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx v xxxxxxxxxxxx xxxx klinickém xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, látky xxxxxxxxx pouze xxx xxxxxxxxxxx použití), xx xxxxxxxx stále.

S1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Exogenní* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); bolasteron; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; klostebol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4,:2,3]-5α-androstane); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); tetrahydrogestrinon (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

(b) Xxxxxxxxx** XXX, pokud jsou xxxxxx exogenně:

Androstendiol (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, ale ne x xxxxxxxx xxxxx xx ně:

5α-androstan-3α,17α-diol	5-androstendion (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx tělo normálně xxxxxxxxx produkuje.

2. Xxxxxxx xxxxxxxxxx látky, zahrnující:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

S2. XXXXXXXXX HORMONY, XXXXXXX XXXXXXX X PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx látky x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxx stimulující erytropoesu (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), peginesatid /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x xxxxxx xxxxxxxxxx xxxxxxx x xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory;

4. Xxxxxxx xxxxxx (XX) a xxxx uvolňující faktory x xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), mechanické xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx faktory ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x vaziva, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx všech xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), inhlalačního xxxxxxxxxxx (maximální xxxxxx xxxxx 54 mikrogramů xx 24 hodin) x salmeterolu, pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx než 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx za pozitivní xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx užíváním terapeutické xxxxxxxxx dávky xxxxx xxx xxxx uvedené xxxxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX MODULÁTORY

Zakázané xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, formestan, letrozol, xxxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale ne x omezením xxxxx xx ně.

3. Ostatní xxxxxxxxxxxxxx látky xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx s xxxxxxxx xxxxx xx ně.

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Xxxxxxxx;

x) Receptor xxxxx xxxxxxxxxx peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated protein xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. AICAR)

S5. XXXXXXXXX A XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (např. xxxxxxxx, nitrožilní xxxxxx xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není zakázáno.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx, xxxxxxx (xxxx. xxxxxxxxx) x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx (xxxxx drospirenonu, xxxxxxxxx a lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx použití (Při Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se stanoveným xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou xx vyžadováno xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx k xx, xxxxx již xxxx xxxxxxx na diuretikum xxxx xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), ale xx x xxxxxxxx xxxxx na xx. Xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx xxxxx x podvod, xx xxxxxx porušit integritu x platnost Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. To zahrnuje xxxxxx x/xxxx úpravu (xxxx. proteázami) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Nitrožilní infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI

Kromě xxxxxxxxx X0 až S5 x M1 až X3 uvedených výše xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně všech xxxxxx případných optických xxxxxxx (např. d- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx do Monitorovacího xxxxxxxx xxx rok 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Nespecifická xxxxxxxxxxx:

Xxxxxxxxx, amfepramon, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx výslovně xxxxxxx v xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):

Xxxxxxxxx (epinefrin)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin***, xxxxxxxx, xxxxxxxxxxxxx, etylefrin, famprofazon, xxxxxxxxxxx, fenkamfamin, fenprometamin, xxxxxxxxxx, hydroxyamfetamin (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x jeho analoga (xxxx. xxxxxxxx, methedron, xxxx-xxxxxxxxxxxxxxxxxxxxx), levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx***, metylendioxymetamfetamin, metylfenidát, xxxxxxxxxxxxxx (dimetylpentylamin), níketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), trimetazidin, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

* Xxxxxxxxxxx xxxxx zahrnuté do Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Zakázané látky.

** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxx xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.

***** Pseudoefedrin xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx vyšší xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. KANABINOIDY

Přírodní (xxxx. hašiš, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx delta9-tetrahydrokanabinol (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx", XXX018, JWH073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx je xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0.10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (FAI)

• Lukostřelba (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Vodní xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Xxxxxxx v xxxxxxxxxxxxx sportech.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx discipliny) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX) (zakázané xxxx Xxxx xxxxxx)

• Lyžování (XXX) - skoky xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis x. 47/2014 Xx. m. x. xxxxx účinnosti xxxx 20.9.2014.

Právní předpis x. 47/2014 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx jich xxxxxx derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.